Since elastin is considered an important biomarker in the progression of aortic aneurysms, spatially designed nanoparticles targeting the elastin protein could facilitate a new dimension to current knowledge of diagnosis and therapy of AAAs. The gene discussed is ELN; the disease is achalasia-alacrima syndrome.